Q1e: We expect 25% ARR growth and adj. EBITDA of DKK -1.9m. Likely to reiterate FY'24 guidance with no material change in demand. FTE reduction lifts '24e-'26e adj. EBITDA by 19-5%.
Q3 ARR ~2% lower vs. ABGSCe, adj. EBITDA better Reiterated guidance requires strong ARR growth in Q4 Long-term case intact: a quality offering in large markets
We expect Q3 ARR of DKK 67m, ’22e ARR of DKK 70m Short-term headwinds; we cut ’22e-‘24e ARR by 10-22% Still a strong long-term case; high growth should return
DKK 60m raise vs. its own ambition of just DKK 20-40m Current guidance assumes no growth-fueling capital raise Cash is abundant on our ests. - M&A on the horizon?
Q3 largely in line with our recently adjusted estimates Aspires to grow ARR by 40-60% in ’22 (ABGSCe 50%) Fine-tuning estimates, FVR maintained at DKK 24-47
Downgrades ’21 ARR guidance by 4.3% at the mid-point… …due to public COVID measures, closing rates & staff churn Peers re-rating, lower estimates, fair value DKK 24-47 (30-60)
Expanded product offering facilitates ARR growth New capital to continue delivering strong SaaS metrics DKK 30-60 FV range derived from intl. and Nordic peers